This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

EARLY SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
7-9 March 2023
Westin Miyako KyotoKyoto, Japan

Shuling Guo, PhD
Vice President, Antisense Drug Discovery at Ionis Pharmaceuticals, Inc.

Profile

Dr. Shuling Guo received her Ph.D. in Molecular Cancer Biology from Duke University and had her postdoctoral training at HHMI/UCLA. Since joining Ionis Pharmaceuticals in 2008, Dr. Guo has been taking on steadily increasing responsibilities, now serving as the Vice President of Drug Discovery. Dr. Guo oversees the overall drug discovery efforts in CardioRenal, Metabolic, and Pulmonary franchises. She manages research activities from target identification, target validation, to the selection of human development candidates. In addition, she is closely involved in the clinical development of RNA therapeutics. Furthermore, over the years, Dr. Guo has managed exploratory research activities including noncoding RNA, autophagy/mitophagy, and nonsense-mediated mRNA decay. To date, Dr. Shuling Guo has published over 70 articles, a majority of which are related to the applications and mechanisms of antisense technology in various therapeutic areas.

Agenda Sessions

  • RNA Therapeutics: A Versatile Drug Discovery Platform

    2:30pm